tailieunhanh - Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecaninduced side effects without obtaining any benefit. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN